CUTR - Cutera laser treatment AviClear for acne gets FDA clearance

Cutera (NASDAQ:CUTR) said the U.S. Food and Drug Administration granted 510(k) clearance to AviClear to treat mild, moderate and severe Acne. The company said AviClear is the first and only energy-based device to receive this designation for treating mild, moderate, and severe acne. The company said that AviClear is a laser treatment and in addition to reducing existing acne, clinical trials have shown that future breakout episodes are shorter, less intense, and more infrequent after the AviClear procedure. CUTR +1.91% pre-market to $46.49

For further details see:

Cutera laser treatment AviClear for acne gets FDA clearance